Acasti Pharma Stock Current Ratio
| ACST Stock | USD 3.36 0.05 1.47% |
Acasti Pharma fundamentals help investors to digest information that contributes to Acasti Pharma's financial success or failures. It also enables traders to predict the movement of Acasti Stock. The fundamental analysis module provides a way to measure Acasti Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Acasti Pharma stock.
| Last Reported | Projected for Next Year | ||
| Current Ratio | 7.73 | 7.69 |
Acasti | Current Ratio |
Acasti Pharma Company Current Ratio Analysis
Acasti Pharma's Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Current Acasti Pharma Current Ratio | 11.13 X |
Most of Acasti Pharma's fundamental indicators, such as Current Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Acasti Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Acasti Current Ratio Driver Correlations
Understanding the fundamental principles of building solid financial models for Acasti Pharma is extremely important. It helps to project a fair market value of Acasti Stock properly, considering its historical fundamentals such as Current Ratio. Since Acasti Pharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Acasti Pharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Acasti Pharma's interrelated accounts and indicators.
Click cells to compare fundamentals
Acasti Current Ratio Historical Pattern
Today, most investors in Acasti Pharma Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Acasti Pharma's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current ratio growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Acasti Pharma current ratio as a starting point in their analysis.
Acasti Pharma Current Ratio |
| Timeline |
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
| Competition |
In accordance with the recently published financial statements, Acasti Pharma has a Current Ratio of 11.13 times. This is 282.47% higher than that of the Pharmaceuticals sector and 59.0% higher than that of the Health Care industry. The current ratio for all United States stocks is notably lower than that of the firm.
Acasti Current Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Acasti Pharma's direct or indirect competition against its Current Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Acasti Pharma could also be used in its relative valuation, which is a method of valuing Acasti Pharma by comparing valuation metrics of similar companies.Acasti Pharma is currently under evaluation in current ratio category among related companies.
Acasti Pharma Current Valuation Drivers
We derive many important indicators used in calculating different scores of Acasti Pharma from analyzing Acasti Pharma's financial statements. These drivers represent accounts that assess Acasti Pharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Acasti Pharma's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 32.1M | 71.2M | 44.9M | 20.5M | 18.5M | 17.5M | |
| Enterprise Value | 18.0M | 20.3M | 14.9M | (6.9M) | (7.9M) | (7.5M) |
Acasti Fundamentals
| Return On Equity | -0.48 | ||||
| Return On Asset | -0.0792 | ||||
| Current Valuation | 6.49 M | ||||
| Shares Outstanding | 9.4 M | ||||
| Shares Owned By Insiders | 16.02 % | ||||
| Shares Owned By Institutions | 12.13 % | ||||
| Number Of Shares Shorted | 1.41 K | ||||
| Price To Earning | 15.34 X | ||||
| Price To Book | 0.49 X | ||||
| Price To Sales | 208.39 X | ||||
| Gross Profit | 120 K | ||||
| EBITDA | 15.85 M | ||||
| Net Income | (42.43 M) | ||||
| Cash And Equivalents | 38.39 M | ||||
| Cash Per Share | 0.86 X | ||||
| Total Debt | 485 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 11.13 X | ||||
| Book Value Per Share | 6.88 X | ||||
| Cash Flow From Operations | (15.91 M) | ||||
| Short Ratio | 0.04 X | ||||
| Earnings Per Share | (5.68) X | ||||
| Target Price | 5.95 | ||||
| Beta | 1.53 | ||||
| Market Capitalization | 31.58 M | ||||
| Total Asset | 79.12 M | ||||
| Retained Earnings | (198.27 M) | ||||
| Working Capital | 25.88 M | ||||
| Current Asset | 11.33 M | ||||
| Current Liabilities | 1.14 M | ||||
| Net Asset | 79.12 M |
About Acasti Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Acasti Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Acasti Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Acasti Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Acasti Pharma in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Acasti Pharma's short interest history, or implied volatility extrapolated from Acasti Pharma options trading.
Pair Trading with Acasti Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Acasti Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Acasti Pharma will appreciate offsetting losses from the drop in the long position's value.Moving together with Acasti Stock
| 0.79 | A | Agilent Technologies Financial Report 28th of May 2024 | PairCorr |
| 0.71 | DSGN | Design Therapeutics Financial Report 14th of May 2024 | PairCorr |
Moving against Acasti Stock
| 0.75 | BNR | Burning Rock BiotechLtd Financial Report 4th of June 2024 | PairCorr |
| 0.64 | NVS | Novartis AG ADR Earnings Call This Week | PairCorr |
| 0.63 | VRTX | Vertex Pharmaceuticals Financial Report 6th of May 2024 | PairCorr |
| 0.56 | VALN | Valneva SE ADR Financial Report 2nd of May 2024 | PairCorr |
The ability to find closely correlated positions to Acasti Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Acasti Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Acasti Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Acasti Pharma to buy it.
The correlation of Acasti Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Acasti Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Acasti Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Acasti Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Acasti Pharma Piotroski F Score and Acasti Pharma Altman Z Score analysis. For more information on how to buy Acasti Stock please use our How to Invest in Acasti Pharma guide.You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Complementary Tools for Acasti Stock analysis
When running Acasti Pharma's price analysis, check to measure Acasti Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acasti Pharma is operating at the current time. Most of Acasti Pharma's value examination focuses on studying past and present price action to predict the probability of Acasti Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acasti Pharma's price. Additionally, you may evaluate how the addition of Acasti Pharma to your portfolios can decrease your overall portfolio volatility.
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |
Is Acasti Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Acasti Pharma. If investors know Acasti will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Acasti Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.68) | Revenue Per Share 0.005 | Return On Assets (0.08) | Return On Equity (0.48) |
The market value of Acasti Pharma is measured differently than its book value, which is the value of Acasti that is recorded on the company's balance sheet. Investors also form their own opinion of Acasti Pharma's value that differs from its market value or its book value, called intrinsic value, which is Acasti Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Acasti Pharma's market value can be influenced by many factors that don't directly affect Acasti Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Acasti Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Acasti Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Acasti Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.